Eton Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ETON in the last 7 days.
HC Wainwright & Co. maintained a Buy rating on Eton Pharmaceuticals with a $70 price target, suggesting a 31.3% upside from the last close. The firm highlights Eton's strong pipeline of rare disease products and the market potential of its recent acquisition, LIBERVANT.
Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) signed an exclusive U.S. licensing agreement for LIBERVANT, a buccal film seizure rescue therapy. Eton gains commercialization rights, while Aquestive will manufacture. The U.S. seizure rescue market is estimated at over $450 million annually. LIBERVANT is expected to launch in April 2027, pending FDA approval. Both companies' stocks showed mixed trading activity.
Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a ma
Recent ETON coverage spans financial news, insider activity and technology.
In the last 30 days, ETON insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($229K). The most active reporter was Krempa David, Chief Business Officer, with 1 filing.
Analyst upgrade with a higher price target may drive buying pressure.
Potential revenue boost from a $450M market opportunity; stock may rise on the licensing news.
Eton gains a differentiated orphan‑drug asset in a $450M seizure‑rescue market.
Positive catalyst from the licensing deal expands Eton's rare‑disease portfolio and could boost its valuation over the long term.
Positive catalyst from a new product licensing deal and upcoming launch.
AlphAI scores every news story that mentions ETON with an AI model for sentiment and relevance, and aggregates insider trades from Eton Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. maintained a Buy rating on Eton Pharmaceuticals with a $70 price target, suggesting a 31.3% upside from the last close. The firm highlights Eton's strong pipeline of rare disease products and the market potential of its recent acquisition, LIBERVANT.
1 min readEton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) signed an exclusive U.S. licensing agreement for LIBERVANT, a buccal film seizure rescue therapy. Eton gains commercialization rights, while Aquestive will manufacture. The U.S. seizure rescue market is estimated at over $450 million annually. LIBERVANT is expected to launch in April 2027, pending FDA approval. Both companies' stocks showed mixed trading activity.
2 min readAquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a ma
2 min readEton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT ® (diazepam) Buccal Film ● Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue tr
2 min readEton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) entered an exclusive license agreement for LIBERVANT, a buccal film for seizure rescue. 71% of surveyed patients preferred the film over nasal spray. The U.S. market for seizure rescue treatments exceeds $450M annually. Eton anticipates commercial launch in April 2027, subject to FDA approval. LIBERVANT has Orphan Drug Designation and patent protection until 2038.
2 min readKrempa David (Chief Business Officer) sold 4,166 shares of Eton Pharmaceuticals, Inc. (ETON) at $55.07 ($0.23M total) on 2026-10-06.
1 min readEton Pharmaceuticals (ETON) announced the U.S. launch of IMPAVIDO, a treatment for leishmaniasis. The company acquired exclusive rights and integrated it into its Eton Cares patient support platform, offering co-pay assistance and expanded access programs. ETON stock closed at $57.68 on Friday, down 3.04%.
2 min readEton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO ® (miltefosine) Capsules ● Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States ● Eton has integrated full Eton Cares® patient support, including $0
2 min readB. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
3 min readMAIER PAUL V sold 50,000 shares of Eton Pharmaceuticals, Inc. (ETON) at an average of $59.07 ($58.64–$61.77, $2.95M total) across 3 trades on 2026-08-28.
1 min read
